NCT03955367

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jun 1, 2019
Primary completion: Jun 1, 2022
Completion date: Jun 1, 2025
First posted: —
Last posted: —
Enrollment: 638
Arms / groups: 2 / —
Source: AACT · ingestion pipeline

Sponsors

Chinese Academy of Medical SciencesLead sponsor
Peking UniversityCollaborator
Zhengzhou UniversityCollaborator
Chongqing Medical UniversityCollaborator
Dalian Medical UniversityCollaborator
Hacettepe UniversityCollaborator
Jilin UniversityCollaborator
Guizhou Medical UniversityCollaborator
Inner Mongolia Medical UniversityCollaborator
Ningxia Medical UniversityCollaborator
Huazhong University of Science and TechnologyCollaborator
Jiao Tong UniversityCollaborator
Sichuan UniversityCollaborator
Chinese Academy of Medical SciencesOverall official - principal investigator
Chinese Academy of Medical SciencesReponsible party - principal investigator
Henan Medical UniversityCollaborator
Capital Medical UniversityCollaborator
Jilin Provincial Tumor HospitalCollaborator
Shengjing HospitalCollaborator
Cangzhou Central HospitalCollaborator
Chinese Academy of Medical SciencesCollaborator
Tangshan People's HospitalCollaborator
Wuhan UniversityCollaborator
Xi’an Gaoxin HospitalCollaborator
Tumor Hospital of GansuCollaborator
People's Liberation Army of ChinaCollaborator
Xinjiang Medical UniversityCollaborator
Jiangsu Cancer Institute & HospitalCollaborator
Harbin Medical UniversityCollaborator
General Hospital of Benxi Iron and Steel CO., LTD.Collaborator

Drugs studied

Indications studied

Uterine Cervical Neoplasms

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.